Analysis of visceral metastasis hormone sensitive prostate cancer: a case report and literature review
10.3760/cma.j.cn112330-20210408-00017
- VernacularTitle:伴有内脏转移的激素敏感性前列腺癌病例分析并文献复习
- Author:
Peng WU
1
;
Weijun QIN
;
Yu LI
;
Shuaijun MA
;
Lichun WEI
;
Jing ZHANG
;
Jing REN
;
Daliang LIU
;
Fuli WANG
;
Chunjuan TIAN
Author Information
1. 空军军医大学西京医院泌尿外科，西安 710032
- Keywords:
Prostatic neoplasms;
Hormone-sensitive;
Whole-course management;
Visceral metastasis
- From:
Chinese Journal of Urology
2021;42(Z1):67-71
- CountryChina
- Language:Chinese
-
Abstract:
Hormone-sensitive prostate cancer with visceral metastasis is a difficulty in clinical diagnosis and treatment. We treated a patient with hormone-sensitive prostate cancer with visceral metastasis and managed it under the multi-disciplinary treatment model (MDT). A 55-year-old man presented to the hospital complaining of increased prostate-specific antigen (PSA) found in the physical examination for 2 days. At admission, the PSA was 389.2ng/ml, and 68Ga-PSMA PET/CT showed metastatic malignant lesions of the prostate, with lymph node metastasis, lumbar vertebral metastases and liver tubercles. Transrectal prostate puncture biopsy: prostate adenocarcinoma, Gleason score of 4+ 5=9. The patient has no history of androgen deprivation therapy (ADT) and diagnosed as metastatic hormone-sensitive prostate cancer (mHSPC). Then the patient received total androgen blockade therapy (CAB regimen). After MDT discussion, metastatic prostate cancer was diagnosed based on the liver histopathology of percutaneous biopsy. After the second MDT discussion, the regimen was changed to abirone plus ADT. After 6 months, the blood PSA was controlled at a level between 0.003 to 0.006 ng/ml, and the testosterone was less than 2.5ng/dl. Re-examination of 68Ga-PSMA PET/CT showed that lower signal of radionuclide in all lesions, especially no more abnormal uptake lesions were identified in the liver.
